Linked Life Data

15126522

Source:http://linkedlifedata.com/resource/pubmed/id/15126522

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15126522rdf:typepubmed:Citationlld:pubmed
pubmed-article:15126522lifeskim:mentionsumls-concept:C0015915lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0733758lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0439682lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0949385lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C1098055lld:lifeskim
pubmed-article:15126522lifeskim:mentionsumls-concept:C2713522lld:lifeskim
pubmed-article:15126522pubmed:issue5lld:pubmed
pubmed-article:15126522pubmed:dateCreated2004-5-5lld:pubmed
pubmed-article:15126522pubmed:abstractTextIn a first feasibility study, the efficacy and safety of a single dose of recombinant long-acting FSH (FSH-CTP) were investigated in in vitro fertilization (IVF) patients undergoing controlled ovarian stimulation with a flexible GnRH antagonist protocol. Eligible subjects were randomized to receive a single dose of 120 micro g (n = 25), 180 microg (n = 24), or 240 microg (n = 25) corifollitropin alfa (FSH-CTP) or to start daily fixed doses of 150 IU recombinant FSH (rFSH) (n = 24, reference). Subjects who received a single dose of FSH-CTP continued 1 wk after injection (treatment d 8) with fixed daily doses of 150 IU rFSH (Puregon/Follistim) until the day of triggering final oocyte maturation. The terminal half-life of FSH-CTP was, on average, 65 h and dose independent. Cycle cancellation before human chorionic gonadotropin (hCG) administration occurred in only three subjects treated with FSH-CTP. The median duration of stimulation was 10.0 d in each FSH-CTP group and 9.0 d in the daily rFSH group. The total number of follicles at least 11 mm at stimulation d 8 and at the day of hCG administration tended to increase with dose of FSH-CTP, although a significant dose-response relationship was revealed only for the number of follicles at least 15 mm on the day of hCG (P = 0.03). Serum estradiol levels and inhibin-B levels were not significantly different between the four groups on d 8 and on the day of hCG. In total, 12 subjects (17.6%) in the FSH-CTP groups and two subjects (8.3%) in the rFSH group experienced a premature LH rise (defined as LH >or= 10 IU/liter) before the start of the GnRH antagonist (P value not significant between groups). This relatively high incidence of women demonstrating an early LH rise in the FSH-CTP groups may be related to the higher initial rises of serum estradiol and the use of a flexible GnRH antagonist protocol. The mean number of oocytes recovered per started cycle was higher in FSH-CTP-treated subjects compared with rFSH-treated subjects (significant at P = 0.03 for the 240- microg FSH-CTP group), but no difference could be noted between the number of good quality embryos (range of means, 3.8-4.8 per attempt), and equal numbers of embryos were available for embryo transfer. In summary, FSH-CTP appeared to be a potent inducer of multiple follicular growth; additional research will be needed to select the optimal FSH-CTP dose and treatment time interval.lld:pubmed
pubmed-article:15126522pubmed:languageenglld:pubmed
pubmed-article:15126522pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:citationSubsetAIMlld:pubmed
pubmed-article:15126522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15126522pubmed:statusMEDLINElld:pubmed
pubmed-article:15126522pubmed:monthMaylld:pubmed
pubmed-article:15126522pubmed:issn0021-972Xlld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:DhontMMlld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:DevroeyPPlld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:FauserB CBClld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:MannaertsB...lld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:PlatteauPPlld:pubmed
pubmed-article:15126522pubmed:authorpubmed-author:BeckersN GNGlld:pubmed
pubmed-article:15126522pubmed:issnTypePrintlld:pubmed
pubmed-article:15126522pubmed:volume89lld:pubmed
pubmed-article:15126522pubmed:ownerNLMlld:pubmed
pubmed-article:15126522pubmed:authorsCompleteYlld:pubmed
pubmed-article:15126522pubmed:pagination2062-70lld:pubmed
pubmed-article:15126522pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:meshHeadingpubmed-meshheading:15126522...lld:pubmed
pubmed-article:15126522pubmed:year2004lld:pubmed
pubmed-article:15126522pubmed:articleTitleInduction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization.lld:pubmed
pubmed-article:15126522pubmed:affiliationCenter for Reproductive Medicine, Dutch-Speaking Brussels Free University, 1090 Brussels, Belgium.lld:pubmed
pubmed-article:15126522pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15126522pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15126522pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15126522pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15126522lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15126522lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15126522lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15126522lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15126522lld:pubmed